‌

US Patent 10399976 Dihydropyrrolopyridine inhibitors of ROR-gamma

Patent 10399976 was granted and assigned to Vitae Pharmaceuticals on September, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Vitae Pharmaceuticals

Current Assignee

Vitae Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

September 3, 2019

Patent Application Number

16025155

Date Filed

July 2, 2018

Patent Citations

US Patent 10087184 Dihydropyrrolopyridine inhibitors of RORγ

US Patent 10047085 Dihydropyrrolopyridine inhibitors of ROR-gamma

Patent Citations Received

US Patent 11834421 Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof

0

US Patent 11001583 Dihydropyrrolopyridine inhibitors of ROR-gamma

US Patent 11008340 Modulators of ROR-gamma

US Patent 11466024 Bicylic compound acting as an inhibitor

US Patent 11535614 Dihydropyrrolopyridine inhibitors of ROR-gamma

US Patent 10807980 Dihydropyrrolopyridine inhibitors of ROR-gamma

US Patent 10829448 Substituted benzoimidazoles as modulators of ROR-γ

US Patent 10913739 Inhibitors of RORγ

Patent Primary Examiner

Niloofar Rahmani

Patent abstract

Provided are novel compounds of Formula (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10399976 Dihydropyrrolopyridine inhibitors of ROR-gamma

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.